
Location: Barcelona - Spain (3 days working from the office and 2 days working from home).
At Alexion, AstraZeneca Rare Disease, this role offers the opportunity to shape access to transformative medicines in areas of high unmet need and make a meaningful impact for patients living with rare haematological diseases. You will operate in a highly visible, strategic position with broad cross-functional exposure, leading portfolio-level market access, pricing, and reimbursement strategy across key markets. This role will have a particular focus on Paroxysmal Nocturnal Hemoglobinuria (PNH) and HSCT-TMA indications. This is an opportunity for an experienced market access leader to influence critical launch and lifecycle decisions, navigate complex payer environments, and play a central role in advancing our ambition within Haematology.
You will join a highly valued strategic team that is fundamental to realizing the potential of our life-changing medicines. Through our work, AstraZeneca ensures that appropriate access is provided to our transformative therapies.
Alexion, AstraZeneca Rare Disease’s Global Value Access and Pricing (GVAP) team is seeking a qualified Director to join a dynamic and growing team. The successful candidate will be responsible for Haematology indication, including near-term new product launches and label expansions.
As a key member of the GVAP team, you will help shape and execute global value, access, and pricing strategies for Haematology indications, with a particular focus on the PNH and HSCT-TMA indications and its lifecycle management.
This is a strategic role that requires an understanding of global healthcare and health technology assessment (HTA) systems, competitive insights, and clinical evidence. You will use this knowledge to shape market access, pricing, and reimbursement success for critical product launches and indications.
The ideal candidate will have deep expertise in global payer, HTA, and reimbursement environments, together with a strong track record of delivering market access, pricing, and reimbursement success within rare diseases and/or Haematology.
15-sept-2026
29-sept-2026
Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law. Alexion provides reasonable accommodations to meet the needs of candidates and employees. To begin an interactive dialogue with Alexion regarding an accommodation, please contact accommodations@Alexion.com. Alexion participates in E-Verify.

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease.
A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.
As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.
GL/NP/0116
GL/NP/0095
Community Guidelines: https://bit.ly/39x9gqy